BioCentury
ARTICLE | Clinical News

Jinarc tolvaptan regulatory update

March 16, 2015 7:00 AM UTC

EMA’s CHMP recommended approval of Jinarc tolvaptan from Otsuka to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults wi...